Results of a new review paper from University of Oxford highlight some consistent differences in #eyemovements between people with #Parkinson's disease and healthy aging in naturalistic scenarios https://t.ly/4ED9i
עלינו
NeuraLight is developing a software-based platform for eye movement analysis, providing an objective and sensitive tool in neurodegenerative diseases. Our platform is successfully used in several CNS clinical trials, presenting the ability of using eye movement analysis to differentiate patients from healthy subjects, stratify different subgroups, and monitor disease progression.
- אתר אינטרנט
-
https://neuralight.ai/
קישור חיצוני עבור NeuraLight
- תעשייה
- Software Development
- גודל החברה
- 11-50 עובדים
- משרדים ראשיים
- Tel Aviv
- סוג
- בבעלות פרטית
- הקמה
- 2021
מיקומים
-
הראשי
Tel Aviv, IL
עובדים ב- NeuraLight
עדכונים
-
A new published paper from Universidad Nacional Autónoma de México on patients with early #Huntington's disease #HD who revealed abnormalities of #eyemovements, suggestive the involvement of brain stem deficits https://t.ly/QbsXn
-
In these days, as the 2024 #NobelPrize announcements are made by The Royal Swedish Academy of Sciences and the Karolinska Institutet, this is a good opportunity to express our gratitude to the distinguished members of NeuraLight advisory board, #NobelPrize laureates Prof. Thomas C. Südhof, MD, PhD, and Prof. Alvin Roth, PhD for their exceptional contribution to the development of #science, #medicine and #healthcare. Thank you! https://t.ly/e5464
Team - NeuraLight
https://neuralight.ai
-
Over the last decades, a large evidence-based knowledge was gathered on the role of #eyemovements as a window to the #brain in #CNS diseases. Check our new NeuraLight website to find out more on the science behind out technology https://t.ly/-PRk8
The Science - NeuraLight
https://neuralight.ai
-
#Eyemovements have been known for decades as a relevant assessment tool for #Alzheimer's disease. This new study examined changes in pupillary responses as potential #biomarkers in patients with mild cognitive impairment #MCI https://t.ly/kPsbw
Task-evoked pupillary responses as potential biomarkers of mild cognitive impairment - PubMed
pubmed.ncbi.nlm.nih.gov
-
Today, October 10th, is #WorldMentalHealthDay. At NeuraLight, we leverage the use #eyemovements as a biomarker for #MentalHealth diseases. See this review on different oculometric characteristics in #schizophrenia. https://t.ly/2Oeg4
Eye movement characteristics in schizophrenia: A recent update with clinical implications
onlinelibrary.wiley.com
-
Check out our cool new website, with a list of all of NeuraLight peer-reviewed publications, presenting the results of using our #eyemovements platform in clinical practice #CNS diseases #Parkinson's #ALS #MS https://t.ly/mLsWu
Publications - NeuraLight
https://neuralight.ai
-
The NeuraLight team attended the congress of the International Parkinson and Movement Disorder Society, where our partners from Rush University Medical Center and Beilinson - Rabin Medical Center presented their work on using our software-based #eyemovements platform in the assessment of patients with #Parkinson's #MDScongress
-
The NeuraLight team attended the ECTRIMS conference, where our joint work with the Copenhagen University Hospital Rigshospitalet and the Danish #Multiplesclerosis registry was presented! #ECTRIMS2024
-
We’re thrilled to announce the launch of our newly designed website for NeuraLight! Visit us at https://neuralight.ai, and learn more of the NeuraLight platform, which leverages #eyemovements to provide clinicians and researchers with an objective measurement tool for #CNS diseases. This innovative technology is part of our ongoing mission to support drug development in the fight against devastating conditions like #Parkinsons, #MS, #ALS, and #Alzheimers.
Home
https://neuralight.ai